ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CPHI / earnings
ABVC (32) BCTX (40) BYSI (37) RNAZ (35) ⌘ Pro Terminal →

China Pharma Holdings Inc. (CPHI) Next Earnings Date & Expected ±12.5% Move

$0.61 -2.98% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.61

China Pharma Holdings Inc. (CPHI) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $26.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CPHI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CPHI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, China Pharma Holdings Inc. (NYSE: CPHI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.61 (-2.98% 1D, market cap $26.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CPHI ranks #606 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CPHI compare to ABVC and BCTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CPHI carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of -3.2%, and ROIC of -11.4%. By comparison, ABVC (ABVC BioPharma Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $26.7M) and BCTX (BriaCell Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M). Among the 5-stock peer group, CPHI leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CPHI?
▼

Per CPHI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001106644), China Pharma Holdings Inc. generated $4.1M in revenue (-8.5% YoY), -$3.2M in net income, and $88.9K in free cash flow against $31.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.61 (-0.73%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 2.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510035
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (6)Whales (8)SEC (8)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.8% Base Target
$20 Bull$1 Base$0 Bear
📬 FREE CPHI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CPHI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY CPHI SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (23% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
43
Grade D$0.75-4% Next Q
Q2 (-2Q)
40
Grade D$0.72-12.5% Next Q
Q3 (-1Q)
38
Grade E$0.63-3.2% Next Q
Current
35
Grade D-$0.61-8.5% Hist 90D α
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CPHI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CPHI currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.74) and Max Pain ($0.64) forces dealer call-delta covering toward $20.15.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CPHI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CPHI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.08 Expected Swing
$1.00 (-12.5%)Spot $0.61$0.69 (+12.5%)
MODEL EARNINGS SETUP GAUGE

CPHI Quantitative Pre-Earnings Setup: 35/100

Trailing EPS: $4.25 • YoY Revenue Growth: -8.5%

Model Bullish Setup (35/100)Model Risk Weight (65/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$4.1M-$3.2M$88.9K-3.2%
FY 20242024-12-31$4.5M-$4.7M-$444.5K-43.8%
FY 20232023-12-31$7.0M-$3.1M-$699.7K8%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CPHI)

  • ✓Walkthrough of CPHI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CPHI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +17.31%⚡ TESTING RESISTANCE
2026-11-03O $0.65H $0.65L $0.61C $0.61VOL 184.3K
RES: $1.25SUP: $0.60SMA50: $0.74SMA200: $0.82
$20.51$15.05$9.60$4.14$-1.31RES $1.25SUP $0.60$0.612026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CPHI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CPHI Butterfly Map → + Track CPHI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -8.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CPHI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CPHI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CPHI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CPHI)

Health Care Rank #606 of 1015 ⚔️ ABVC vs CPHI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CPHI vs. ABVC, BCTX, BYSI, RNAZ)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, China Pharma Holdings Inc. (CPHI) ranks #606 by composite RQD confidence (35/100, grade D-) and #808 by equity capitalization ($26.9M). Within this direct 5-issuer industry benchmark cohort, CPHI leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. BCTX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with CPHI at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CPHI ACTIVE
China Pharma Holdings Inc.
D- 35/100 — -3.2% -11.4% -2.98% $26.9M Benchmark Subject
ABVC
ABVC BioPharma Inc.
E 32/100 — — -35.0% -1.99% $26.7M /abvc-vs-cphi →
BCTX
BriaCell Therapeutics Corp.
D- 40/100 — — — +1.65% $26.5M /bctx-vs-cphi →
BYSI
BeyondSpring Inc.
D- 37/100 — — -35.0% +25.18% $26.5M /bysi-vs-cphi →
RNAZ
TransCode Therapeutics Inc.
D- 35/100 — — -35.0% 0.00% $27.6M /rnaz-vs-cphi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001106644 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), China Pharma Holdings Inc. (CPHI) reported GAAP revenue of $4.1M (-8.5% vs. FY2024 revenue of $4.5M , and -40.9% cumulative change since FY2023) , GAAP net income of -$3.2M, operating cash flow of $148.3K, and free cash flow of $88.9K (+120.0% YoY). On the balance sheet, CPHI closed FY2025 with $31.0M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $4.1M -$3.2M $148.3K $88.9K $31.0M —
FY2024 (FY) 2024-12-31 $4.5M -$4.7M -$406.1K -$444.5K $14.9M —
FY2023 (FY) 2023-12-31 $7.0M -$3.1M -$699.7K -$699.7K — —

3. CPHI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CPHI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, China Pharma Holdings Inc. (NYSE: CPHI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.61 (-2.98% 1D, market cap $26.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CPHI ranks #606 in composite RQD confidence.

How does CPHI compare to ABVC and BCTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CPHI carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of -3.2%, and ROIC of -11.4%. By comparison, ABVC (ABVC BioPharma Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $26.7M) and BCTX (BriaCell Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M). Among the 5-stock peer group, CPHI leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CPHI?

Per CPHI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001106644), China Pharma Holdings Inc. generated $4.1M in revenue (-8.5% YoY), -$3.2M in net income, and $88.9K in free cash flow against $31.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CPHI trading relative to its 50-day, 200-day, and 52-week technical levels?

CPHI last traded at $0.61 (-2.98% on volume of 105,409 shares), positioning the stock -17.57% below its 50-day simple moving average ($0.74) and -25.61% below its 200-day simple moving average ($0.82). Across its 52-week range of $0.38 to $19.19, CPHI sits at the 1.2% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.69).

Direct Sub-Reports: CPHI RQD Cockpit CPHI 12M Forecast CPHI Earnings & Move CPHI Dividends & DRIP CPHI Insiders & 13F CPHI Whale Options CPHI Profit Sankey CPHI News & Why
ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

CPHI — China Pharma Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

China Pharma Holdings Inc. (CPHI) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.61 (-2.98% 1D, market capitalization $26.9M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -11.4%, gross margin of -3.2%, operating margin of -60.0%, and free cash flow yield of 0.32%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

China Pharma Holdings Inc. Is a NYSE-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations..0B on a rounded basis, consistent with the $28.0M figure in market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), China Pharma Holdings Inc. (CPHI) reported $4.1M in annual revenue (up from $4.5M in FY2024, -8.5% YoY) and -$3.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($7.0M revenue, -$3.1M net income) through FY2025, CPHI scaled operating cash flow to $148.3K and free cash flow to $88.9K, backed by $31.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.32% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.38 – $19.19 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — Investors should note that the absence of mapped links means the source data cannot identify which suppliers, customers, or peers would transmit shocks to CPHI.

  • Key Question #1: Can CPHI sustain or expand its -60.0% operating margin and -11.4% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $4.1M and free cash flow of $88.9K, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CPHI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CPHI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for China Pharma Holdings Inc. (CPHI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CPHI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CPHI Bull vs. Bear Conversation Board — What's Your Call at $0.61?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CPHI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CPHI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $0.81 (+30.6%)
📌 Pinned Debate

The stock trades at $0.65 with a $28.0M market cap, far below its prior 52-week high of $19.19, leaving room for recovery if the busine

Here is why I am bullish on CPHI here at $0.62: The stock trades at $0.65 with a $28.0M market cap, far below its prior 52-week high of $19.19, leaving room for recovery if the business stabilizes.. Compare CPHI's -60.0% operating margin and -11.4% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $0.59 are getting bought.

VolSurface_Trader 🐂 BULL

Both sides have a point here — CPHI's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $0.51 (-17.7%)
Spot @ $0.62

With an Altman Z-Score of 0.2, ROIC of -11.4%, and net margin of -60%, the company shows severe financial distress with no reported pat

Sitting on the sidelines or leaning short CPHI above $0.62. With an Altman Z-Score of 0.2, ROIC of -11.4%, and net margin of -60%, the company shows severe financial distress with no reported path to profitability.. Until Fundamental Cash Engine (6/20) and FCF yield (0.32%) inflect higher, upside is capped near $19.19.

LIVE TAPE